Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas
暂无分享,去创建一个
N. Raj | P. Munster | L. Fong | Li Zhang | T. Hope | R. Aggarwal | K. Kolli | E. Bergsland | J. Grabowsky | Claire K. Mulvey | K. Perez | Claire K Mulvey | J. A. Chan | S. Calabrese | D. Reidy‐Lagunes | Stephanie J. Wang | April DeMore | Sippy Punn | Sofia Von Fedak | Kimberly Perez
[1] Wei Peng,et al. Complete Response to Immunotherapy Combined With Chemotherapy in a Patient With Gynecological Mixed Cancer Mainly Composed of Small Cell Neuroendocrine Carcinoma With High Tumor Mutational Burden: A Case Report , 2022, Frontiers in Oncology.
[2] L. Seymour,et al. iRECIST and atypical patterns of response to immuno-oncology drugs , 2022, Journal for ImmunoTherapy of Cancer.
[3] J. Nemunaitis,et al. Small-cell breast carcinoma with response to atezolizumab: a case report. , 2022, Immunotherapy.
[4] A. Sweet-Cordero,et al. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer , 2022, Frontiers in Oncology.
[5] J. Strosberg,et al. Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms , 2021, ESMO open.
[6] Chien-Feng Li,et al. Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden , 2021, Current oncology.
[7] E. Polo,et al. 1098O Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913) , 2021, Annals of Oncology.
[8] P. Nuciforo,et al. 1107P Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601) , 2021, Annals of Oncology.
[9] N. Girard,et al. LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC) , 2021, Annals of Oncology.
[10] Helen X. Chen,et al. A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort , 2021, Cancer.
[11] C. Sung,et al. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas , 2021, Scientific Reports.
[12] A. Fojo,et al. Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors , 2021, The oncologist.
[13] M. Dominici,et al. PD-1 blockade in deficient mismatch repair mixed adenoneuroendocrine carcinoma of the stomach: new hope for an orphan disease , 2020, Tumori.
[14] R. García-Carbonero,et al. 1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601) , 2020 .
[15] M. Ronot,et al. Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability , 2020, Neuroendocrinology.
[16] P. Engstrom,et al. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials , 2020, British Journal of Cancer.
[17] P. Ascierto,et al. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] D. Planchard,et al. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[19] L. Shen,et al. Hyperprogression after immunotherapy in patients with malignant tumors of digestive system , 2019, BMC Cancer.
[20] M. Ronot,et al. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study. , 2019, The oncologist.
[21] A. Olshen,et al. Next-Generation Sequencing of Uveal Melanoma for Detection of Genetic Alterations Predicting Metastasis , 2019, Translational Vision Science & Technology.
[22] E. Baudin,et al. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors , 2019, BMC Cancer.
[23] L. Shen,et al. Efficacy and safety of PD-1 blockade with JS001 in patients with advanced neuroendocrine neoplasms: A non-randomized, open-label, phase Ib trial. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] H. Sorbye,et al. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases , 2018, Cancer.
[25] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[26] W. Hahn,et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. , 2014, The Journal of molecular diagnostics : JMD.
[27] Kai Ye,et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..
[28] J. Soria,et al. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. , 2014, European urology.
[29] G. Scagliotti,et al. Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. , 2014, Human pathology.
[30] Neelam Gulati,et al. Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome. , 2014, Journal of the American College of Surgeons.
[31] D. Reidy-Lagunes,et al. The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas. , 2013, Seminars in oncology.
[32] J. Maguire,et al. Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing , 2009, Nature Biotechnology.
[33] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.